SSY Group (HK:2005) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SSY Group has successfully included two of its drugs, Stiripentol Dry Suspension and Etomidate Medium/Long Chain Fat Emulsion Injection, in China’s 2024 National Reimbursement Drug List. Stiripentol, a treatment for severe myoclonic epilepsy in children, is exclusively produced domestically by SSY, while Etomidate is utilized for general anesthesia induction. This development marks a significant milestone for SSY Group, enhancing its market presence in China.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
